Glycoengineering Chinese hamster ovary cells: a short history
Open Access
- 11 March 2021
- journal article
- review article
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 49 (2) , 915-931
Abstract
Biotherapeutic glycoproteins have revolutionised the field of pharmaceuticals, with new discoveries and continuous improvements underpinning the rapid growth of this industry. N-glycosylation is a critical quality attribute of biotherapeutic glycoproteins that influences the efficacy, half-life and immunogenicity of these drugs. This review will focus on the advances and future directions of remodelling N-glycosylation in Chinese hamster ovary (CHO) cells, which are the workhorse of recombinant biotherapeutic production, with particular emphasis on antibody products, using strategies such as cell line and protein backbone engineering.Keywords
This publication has 154 references indexed in Scilit:
- Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal AntibodiesJournal of the American Chemical Society, 2013
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Polymeric human Fc-fusion proteins with modified effector functionsScientific Reports, 2011
- The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell lineNature Biotechnology, 2011
- Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucoseProceedings of the National Academy of Sciences, 2011
- Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteinsNature Biotechnology, 2010
- Glycomics Profiling of Chinese Hamster Ovary Cell Glycosylation Mutants Reveals N-Glycans of a Novel Size and ComplexityJournal of Biological Chemistry, 2010
- Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG FcScience, 2008
- A Model for Neuronal Competition During DevelopmentScience, 2008
- Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-GalactoseNew England Journal of Medicine, 2008